Early after initiation of anti-PD-1 therapy, an increase in the frequency of the circulating CX3CR1+ CD8+ T cells is associated with improved response and survival in NSCLC patients (179). This evidence concerns the gene CX3CR1 and non-small cell lung carcinoma.